Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) Sees Significant Increase in Short Interest

Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) was the recipient of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 700 shares, a growth of 16.7% from the February 13th total of 600 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average trading volume of 17,100 shares, the short-interest ratio is currently 0.0 days.

Tema Cardiovascular and Metabolics ETF Stock Up 0.5 %

Shares of HRTS traded up $0.14 during mid-day trading on Thursday, hitting $30.19. The company had a trading volume of 2,972 shares, compared to its average volume of 13,230. Tema Cardiovascular and Metabolics ETF has a 1-year low of $28.56 and a 1-year high of $36.03. The business’s 50-day simple moving average is $30.01 and its 200-day simple moving average is $31.62. The stock has a market cap of $69.44 million, a PE ratio of 32.63 and a beta of 0.93.

Institutional Trading of Tema Cardiovascular and Metabolics ETF

An institutional investor recently raised its position in Tema Cardiovascular and Metabolics ETF stock. Sterling Investment Advisors Ltd. lifted its holdings in Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) by 5.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 167,703 shares of the company’s stock after acquiring an additional 9,008 shares during the period. Tema Cardiovascular and Metabolics ETF makes up 1.2% of Sterling Investment Advisors Ltd.’s portfolio, making the stock its 24th biggest position. Sterling Investment Advisors Ltd. owned about 7.29% of Tema Cardiovascular and Metabolics ETF worth $4,842,000 as of its most recent SEC filing.

Tema Cardiovascular and Metabolics ETF Company Profile

The Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive.